Participated in Beren Therapeutics' $135M equity financing within a $300M combined financing package.
Beren Therapeutics is a biotechnology company focused on developing treatments for Niemann-Pick disease type C
Beren Therapeutics is a biotechnology company focused on developing treatments for Niemann-Pick disease type C. Their drug adrabetadex received FDA Breakthrough Therapy Designation in 2025. The company aims to deliver novel therapies for rare genetic diseases.